Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient.

Komargodski R, Wittenberg A, Bahat H, Rachmiel M

Pediatrics1 Jul 2024Cited by 2 (Europe PMC)

PMID38864114DOI10.1542/peds.2023-063719PepBankPUB-38864114

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesSafety outcome
A 17-year-old with class III obesity developed acute kidney injury after 3 months of liraglutide 0.6 mg/day; it resolved one month after stopping.
In plain wordsA 17-year-old boy developed acute kidney injury after 3 months of low-dose liraglutide; it resolved after stopping the drug.
Peptide
Liraglutide
Outcome
IncreaseAcute kidney injury
Study
n = 1
Outcome group
Adverse events · Kidney and urinary
Studied dose
0.6 mg/day · 3 monthsAs given in this study (human).
Source sentences
Summary
We present a 17-year-old male who developed AKI and evidence of hepatic injury (significant elevation of hepatic transaminases) after 3 months administration of the lowest dosage of liraglutide (0.6 mg/day) for management of class III obesity.
1 context sentence(design, population, supporting numbers)
Summary · context
One month after discontinuing liraglutide, his mood had improved, his liver enzymes had returned to normal, and AKI had resolved.
Report a problemFND-3886411401
02HumanCase report or seriesSafety outcome
A 17-year-old with class III obesity had significant elevation of hepatic transaminases after 3 months of liraglutide 0.6 mg/day; liver enzymes returned to normal one month after stopping.
In plain wordsA 17-year-old boy had raised liver enzymes after 3 months of low-dose liraglutide; they returned to normal after stopping.
Peptide
Liraglutide
Outcome
IncreaseHepatic transaminase elevation
Study
n = 1
Outcome group
Liver fat and liver function · Liver
Studied dose
0.6 mg/day · 3 monthsAs given in this study (human).
Source sentences
Summary
We present a 17-year-old male who developed AKI and evidence of hepatic injury (significant elevation of hepatic transaminases) after 3 months administration of the lowest dosage of liraglutide (0.6 mg/day) for management of class III obesity.
1 context sentence(design, population, supporting numbers)
Summary · context
One month after discontinuing liraglutide, his mood had improved, his liver enzymes had returned to normal, and AKI had resolved.
Report a problemFND-3886411402
03HumanCase report or seriesSafety outcome
A 17-year-old with class III obesity had significant loss of appetite during liraglutide treatment.
In plain wordsA 17-year-old boy lost his appetite significantly while taking liraglutide.
Peptide
Liraglutide
Outcome
DecreaseLoss of appetite
Study
n = 1
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.6 mg/day · 3 monthsAs given in this study (human).
Source sentences
Summary
The patient experienced significant loss of appetite, weight loss, and melancholy during the treatment period.
Report a problemFND-3886411403
04HumanCase report or seriesEfficacy outcome
A 17-year-old with class III obesity lost weight during liraglutide treatment.
In plain wordsA 17-year-old boy lost weight while taking liraglutide.
Peptide
Liraglutide
Outcome
DecreaseWeight loss
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg/day · 3 monthsAs given in this study (human).
Source sentences
Summary
The patient experienced significant loss of appetite, weight loss, and melancholy during the treatment period.
Report a problemFND-3886411404
05HumanCase report or seriesSafety outcome
A 17-year-old with class III obesity experienced melancholy during liraglutide treatment; mood improved one month after stopping.
In plain wordsA 17-year-old boy felt melancholy while taking liraglutide; his mood improved after stopping.
Peptide
Liraglutide
Outcome
IncreaseMelancholy
Study
n = 1
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
0.6 mg/day · 3 monthsAs given in this study (human).
Source sentences
Summary
The patient experienced significant loss of appetite, weight loss, and melancholy during the treatment period.
1 context sentence(design, population, supporting numbers)
Summary · context
One month after discontinuing liraglutide, his mood had improved, his liver enzymes had returned to normal, and AKI had resolved.
Report a problemFND-3886411405
06HumanCase report or seriesSafety outcome
In this case, the Adverse Drug Reaction Probability Scale suggested a high likelihood of a causative link between liraglutide and the patient's symptoms.
In plain wordsIn this one case, a standard scale rated a causal link between liraglutide and the symptoms as highly likely.
Peptide
Liraglutide
Outcome
Not applicableCausality assessment (Adverse Drug Reaction Probability Scale)
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
0.6 mg/day · 3 monthsAs given in this study (human).
Source sentences
Summary
The Adverse Drug Reaction Probability Scale suggested a high likelihood of a causative association between liraglutide and his symptoms.
Report a problemFND-3886411406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.